PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: A meta-analysis of published clinical trials

Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. However, associations between PIK3CA mutation status and clinical outcomes among patients with HR+/HER2- mBC have been heterogeneous across clinical trials.